Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 4/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13637653 | 0.90 | TRPV1 (0.38) | ROCK2PTPN1RORC | |
| SCHEMBL13628261 | 0.85 | GPBAR1 (0.51) | GPBAR1LMNANT5ESMN1; SMN2RORC | |
| SCHEMBL4444101 | 0.85 | GPBAR1 (0.51) | GPBAR1LMNANT5ESMN1; SMN2RORC | |
| SCHEMBL13637642 | 0.84 | LMNA (0.41) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| SCHEMBL13637475 | 0.84 | RORC (0.38) | PTPN1RORC | |
| SCHEMBL13637644 | 0.80 | GPBAR1 (0.38) | GPBAR1POLBLMNANT5ESMN1; SMN2 | |
| SCHEMBL13637774 | 0.80 | RORC (0.37) | ROCK2PTPN1RORC | |
| SCHEMBL13637490 | 0.80 | RORC (0.40) | PTPN1RORC | |
| SCHEMBL4441761 | 0.79 | GPBAR1 (0.53) | GPBAR1LMNANT5ESMN1; SMN2RORC | |
| SCHEMBL13637669 | 0.79 | GPBAR1 (0.53) | GPBAR1LMNANT5ESMN1; SMN2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | ROCK2 3565/4885GPBAR1 3262/4885POLB 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.